SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Cary C who wrote (10216)7/13/1999 8:22:00 PM
From: majormember  Respond to of 59879
 
Hi Cary,

CNBC just aired a very POSITIVE piece on VPHM.

Goldman analyst said price could easily surpass his $25 target,
another said price could triple. A very professional piece of
P/R that money can't buy.......I bought today, and expect this
to gap and continue going.....this is without Mark's TA, which
imho, confirms the move up we will be seeing tomorrow.

Of course, there will be more positive P/R from CNBC
ALL DAY, commenting on the first possible drug to fight
VIRAL infections.

Cheers,
Skane

P.S. have you looked at BANY? also where to post on
"invitational" thread......anywhere?



To: Cary C who wrote (10216)7/13/1999 8:35:00 PM
From: SnowShredder  Respond to of 59879
 
Hi Cary, Thanks for the links...very interesting stuff...one of these days I'll have to do a medline search on it and read more on the mechanism. Sounds very promising, as antiviral treatments are very hard to come by. Best of Luck, Where'd He Go?

No time to read right now, but if anyone is interested here is a link to some journal abstracts :)

ncbi.nlm.nih.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News